Educational information only. Not medical advice. Talk to a qualified healthcare professional before using any compound. Disclaimer

LimitlessLab
Search the library Wishlist Cart, items: 0
BPC-157

Recovery & Healing

BPC-157

Also known as Body Protection Compound-157, Bepecin, PL 14736, PL-10; half of the Wolverine blend

Limited human evidenceNot approvedWADA prohibited

Price range: €47 through €81

Discussed for: Tendon, ligament, muscle and gut healing.

FIG. 2 ยท Amino-acid sequence of BPC-157 (15 residues)
  1. G
  2. E
  3. P
  4. P
  5. P
  6. G
  7. K
  8. P
  9. A
  10. D
  11. D
  12. A
  13. G
  14. L
  15. V
  • Hydrophobic
  • Polar
  • Positive charge
  • Negative charge
  • Glycine / proline
Effect strengthHow hard it acts on the body5/10
Proof levelHow well that is shown in humans2/10
Risk levelHow much can go wrong5/10

Editorial 1 to 10 estimates from published research, not measured values. How to read these

Save to wishlist
Save to wishlist

01 / Identity

What it is

BPC-157 is a synthetic peptide from gastric protein (15 aa). Main reported uses: tendon, ligament, muscle and gut healing. Current status: not approved anywhere. FDA flagged it as a compounding safety risk (2023).

Molecule type
Synthetic peptide from gastric protein (15 aa)
How it is taken
Injection (SC), oral
Other names
Body Protection Compound-157, Bepecin, PL 14736, PL-10; half of the Wolverine blend

Route only. This library does not publish doses or protocols.

02 / Mechanism

How it is thought to work

Promotes new blood vessel growth (angiogenesis) and tissue repair

Mechanisms seen in cells or animals do not always happen the same way in people.

03 / Potential benefits

What people use it for

Tendon, ligament, muscle and gut healing

Limited human evidence

Small or low-quality human data. Most of what is claimed comes from animals, cells or anecdotes.

Listed uses are what people use it for, not proven outcomes.

04 / Known risks

Side effects and risks

Unknown long-term; angiogenesis raises theoretical cancer concern

Risk level 5 of 10

Moderate risk score: real side effects are known, and long-term safety is not settled.

Unknown long-term effects count as a risk, not as a clean record.

05 / Regulatory

Regulatory status

Status
Not approved
Details
Not approved anywhere. FDA flagged it as a compounding safety risk (2023)
Sport (WADA)
Yes: S0 (named explicitly)

Status reflects information up to mid-2026 and changes over time. Check current sources.

06 / Evidence quality

How good is the evidence?

Limited: mostly animal; very few human studies

How we grade evidence

07 / Notes and sources

Notes and sources

  • In 2023 the FDA placed it on its list of bulk substances with significant safety concerns for compounding.
  • Growth-factor peptides carry a theoretical risk of feeding existing cancers.
  • Products sold online as research peptides are unregulated. Tests of such products often find wrong amounts, impurities or a different compound.
  • Anyone using compounds like this regularly should have medical supervision and bloodwork (for example IGF-1, glucose and HbA1c, hormones, lipids).
  • Source: Peptide Reference Table, an editorial review of published research up to mid-2026. Scores are 1 to 10 editorial estimates, not measured values. Regulatory and WADA status change over time.

Educational information only. Not medical advice. Talk to a qualified healthcare professional before using any compound.

Related compounds